HC Wainwright restated their buy rating on shares of TransCode Therapeutics (NASDAQ:RNAZ – Free Report) in a research note published on Friday, Benzinga reports. They currently have a $3.00 target price on the stock.
TransCode Therapeutics Stock Down 3.1 %
Shares of TransCode Therapeutics stock opened at $0.26 on Friday. The company has a 50-day moving average of $0.45 and a two-hundred day moving average of $0.74. TransCode Therapeutics has a 12-month low of $0.22 and a 12-month high of $128.00.
TransCode Therapeutics (NASDAQ:RNAZ – Get Free Report) last released its quarterly earnings data on Wednesday, August 14th. The company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.58) by ($0.16). As a group, equities research analysts forecast that TransCode Therapeutics will post -2.05 earnings per share for the current year.
Hedge Funds Weigh In On TransCode Therapeutics
TransCode Therapeutics Company Profile
TransCode Therapeutics, Inc, a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others.
Read More
- Five stocks we like better than TransCode Therapeutics
- What Are Dividends? Buy the Best Dividend Stocks
- Why Block’s Key Components Make It a Solid Investment Choice
- How to Choose Top Rated Stocks
- Is Applied Digital’s Stock Set to Surge With NVIDIA’s Backing?
- There Are Different Types of Stock To Invest In
- 4 Reasons to Consider Adding General Mills to Your Portfolio
Receive News & Ratings for TransCode Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransCode Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.